2015-11-09T16:43:44-06:00 2014-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 650N BETHESDA MD 208142930 990 2014-01-01 911157127 PATH PATH 2062853500 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 STEVE DAVIS CHIEF FINANCIAL OFFICER 2062853500 2015-11-09 1 3019519090 2014 2016-04-25 22:37:26Z STEVE DAVIS 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 346979287 0 X WWW.PATH.ORG X 1981 WA SEE PART III, LINE 1. 15 15 746 0 0 0 260656932 286891535 3946 22378 2050396 1565398 2433300 801633 265144574 289280944 72704584 71872357 0 0 101626168 110831078 0 0 3257077 111371191 93920413 285701943 276623848 -20557369 12657096 485822280 495616246 57067664 54206418 428754616 441409828 X OUR MISSION IS TO IMPROVE THE HEALTH OF PEOPLE AROUND THE WORLD BY ADVANCING TECHNOLOGIES, STRENGTHENING SYSTEMS, AND ENCOURAGING HEALTHY BEHAVIORS. (CONTINUED ON SCHEDULE O) 0 0 108848538 39768359 750 PRODUCT DEVELOPMENT: PATH IS A GLOBAL LEADER IN IDENTIFYING, DEVELOPING, AND INTRODUCING AFFORDABLE, EFFECTIVE, AND EASY-TO-USE HEALTH TECHNOLOGIES TO ADDRESS URGENT HEALTH CHALLENGES. OUR VACCINES, DRUGS, DIAGNOSTICS, DEVICES AND TOOLS, AND DIGITAL HEALTH SOLUTIONS ARE EMPOWERING COMMUNITIES AND TRANSFORMING HEALTH WORLDWIDE, PARTICULARLY IN LOW-RESOURCE SETTINGS.PATH SPECIALIZES IN USHERING HEALTH TECHNOLOGIES AND SYSTEMS INNOVATIONS ALL THE WAY FROM BRIGHT IDEA TO LIFESAVING USE IN COMMUNITIES AROUND THE WORLD. WE OVERCOME BARRIERS ON THIS "JOURNEY OF INNOVATION," INCLUDING MARKET CONCERNS, GAPS IN DEMAND AND SUPPLY, POLICY AND REGULATORY ROADBLOCKS, INTRODUCTION, AND OTHER CONSIDERATIONS TO ENSURE THAT SMART SOLUTIONS REACH THE PEOPLE WHO NEED THEM. KEY TO THIS EFFORT IS OUR WORK TO ACCELERATE THE DEVELOPMENT AND DELIVERY OF SAFE, EFFECTIVE, AND LOW-COST VACCINES AGAINST DISEASES THAT THREATEN WOMEN AND CHILDREN WORLDWIDE, INCLUDING THOSE THAT ARE NOT WELL-RECOGNIZED IN WEALTHY COUNTRIES. OUR PORTFOLIO INCLUDES VACCINES FOR DIARRHEAL DISEASE, INFLUENZA, JAPANESE ENCEPHALITIS, MALARIA, MENINGITIS, PNEUMOCOCCAL DISEASE, POLIO, AND MORE. WE ALSO ADVANCE INNOVATIVE DELIVERY STRATEGIES TO HELP VACCINES REACH THE PEOPLE WHOSE LIVES THEY CAN PROTECT. IN 2014, OUR EFFORTS BROUGHT VACCINES TO MORE COMMUNITIES (SOME FOR THE FIRST TIME); ADVANCED PROMISING NEW VACCINE CANDIDATES; AND STRENGTHENED THE SUPPLY CHAINS AND SYSTEMS NECESSARY FOR SAFE VACCINE DELIVERY, STORAGE, AND ADMINISTRATION. FOR EXAMPLE, WE COLLABORATED WITH COUNTRY LEADERS AND PARTNERS IN CAMBODIA, INDIA, AND LAOS TO BRING A SAFE AND EFFECTIVE VACCINE AGAINST JAPANESE ENCEPHALITIS TO AN ESTIMATED 14 MILLION MORE CHILDREN. WE ALSO LAID THE GROUNDWORK FOR ITS INTRODUCTION IN ADDITIONAL REGIONS AND COUNTRIES. JAPANESE ENCEPHALITIS, OFTEN CALLED "BRAIN FEVER," IS AN INCURABLE DISEASE COMMON IN SOUTHEAST ASIA AND THE WESTERN PACIFIC. VACCINE INTRODUCTIONS ARE A CRUCIAL STEP IN A PATH-LED PROCESS THAT HAS INCLUDED IDENTIFYING THE LITTLE-KNOWN VACCINE IN CHINA, PROVING THAT IT IS SAFE AND EFFECTIVE, HELPING THE CHINESE MANUFACTURER ENSURE A GLOBAL SUPPLY, AND SECURING AN AFFORDABLE PUBLIC-SECTOR PRICE. WE ALSO USHERED THE VACCINE THROUGH WORLD HEALTH ORGANIZATION PREQUALIFICATION, WHICH MAKES IT EASIER FOR COUNTRIES TO OBTAIN FUNDING TO PURCHASE AND ROLL OUT THE VACCINE. IN 2014, WE ALSO REACHED 64 MILLION AFRICANS WITH THE MENAFRIVAC VACCINE, DEVELOPED BY PATH, WHO, AND THE SERUM INSTITUTE OF INDIA LTD. TO PROTECT CHILDREN AND YOUNG PEOPLE FROM DEADLY AND DEBILITATING MENINGITIS A. SINCE THE VACCINE'S INTRODUCTION IN 2010, MORE THAN 217 MILLION PEOPLE HAVE BEEN IMMUNIZED. IN 2014, WE CELEBRATED A CAPSTONE ACHIEVEMENT FOR THIS 14-YEAR EFFORT: THE WORLD HEALTH ORGANIZATION DETERMINED THAT, STARTING IN 2015, THE VACCINE CAN SAFELY BE INCLUDED IN ROUTINE IMMUNIZATIONS FOR INFANTS. THIS WILL HELP ENSURE BROAD PROTECTION INTO THE FUTURE. [MENAFRIVAC IS A REGISTERED TRADEMARK OF SERUM INSTITUTE OF INDIA LTD.]WE'RE ALSO ACCELERATING THE DEVELOPMENT OF MORE THAN 20 MALARIA VACCINE CANDIDATES AND APPROACHES. THIS YEAR, THE PIVOTAL PHASE 3 TRIAL OF ONE OF THESE-THE RTS, S MALARIA VACCINE CANDIDATE-CONCLUDED, AND OUR DEVELOPMENT PARTNER, GLAXOSMITHKLINE, SUBMITTED THE FILE FOR REGULATORY REVIEW. THIS WORK PAVED THE WAY FOR A POSITIVE SCIENTIFIC OPINION FROM EUROPEAN REGULATORS IN 2015, AND OPENED THE DOOR FOR A RECOMMENDATION BY THE WORLD HEALTH ORGANIZATION, ANTICIPATED IN LATE 2015. BOTH WILL SUPPORT WIDER ADOPTION AND INTRODUCTION OF THE VACCINE. AN AFFORDABLE NEW VACCINE AGAINST THE MOST LETHAL FORM OF DIARRHEA, ROTAVAC, WAS ALSO A FOCUS. THE VACCINE REDUCES SEVERE ROTAVIRUS DIARRHEA BY 56 PERCENT IN THE FIRST YEAR OF LIFE AT A FRACTION OF THE PRICE OF CURRENTLY AVAILABLE VACCINES. IN EARLY 2014, ROTAVAC OBTAINED LICENSURE IN INDIA, AND IN JULY 2014, THE PRIME MINISTER ANNOUNCED THAT IT WILL BE INCLUDED IN THE NATIONAL IMMUNIZATION PROGRAM. [ROTAVAC IS A REGISTERED TRADEMARK OF BHARAT BIOTECH INTERNATIONAL LTD.]FINALLY, THE BETTER IMMUNIZATION DATA INITIATIVE, A COLLABORATION BETWEEN PATH AND SUB-SAHARAN AFRICAN COUNTRIES, CONTINUED TO EMPOWER NATIONAL HEALTH SYSTEMS TO ENHANCE IMMUNIZATION THROUGH IMPROVED DATA COLLECTION, QUALITY, AND USE. THE INITIATIVE PARTNERED WITH MORE THAN 12 COUNTRIES TO DESIGN EFFECTIVE, SCALABLE INTERVENTIONS AND WORKED DIRECTLY WITH TWO DEMONSTRATION COUNTRIES, TANZANIA AND ZAMBIA, TO IMPROVE ROUTINE IMMUNIZATION SERVICE DELIVERY. IN 2014, FOR INSTANCE, WE LAID THE GROUNDWORK FOR THE 2015 LAUNCH OF A NEW NATIONAL ELECTRONIC IMMUNIZATION REGISTRY IN TANZANIA. THE REGISTRY WILL HELP HEALTH WORKERS TRACK CHILDREN'S IMMUNIZATIONS, FLAG THOSE WHO HAVE MISSED A POTENTIALLY LIFESAVING VACCINE, AND ALERT CAREGIVERS.PATH'S IMPORTANT DRUG DEVELOPMENT WORK CONTINUED IN 2014. OUR EFFORTS FOCUS ON DEVELOPING AND ENSURING THE AVAILABILITY AND ACCESSIBILITY OF SAFE AND EFFECTIVE DRUGS FOR DISEASES THAT DISPROPORTIONATELY AFFECT PEOPLE IN LOW-INCOME COUNTRIES. THESE INCLUDE DIARRHEA, PARASITIC DISEASES, HIV, MALARIA, AND INFECTIONS THAT THREATEN YOUNG CHILDREN AND NEWBORNS. THIS YEAR, 1.7 MILLION MALARIA TREATMENTS MADE WITH A NOVEL INGREDIENT CALLED SEMISYNTHETIC ARTEMISININ WERE DELIVERED TO BURUNDI, LIBERIA, NIGER, AND OTHER COUNTRIES. THE ROLLOUT OF THESE MALARIA TREATMENTS WAS A KEY MILESTONE FOR A GLOBAL PARTNERSHIP CONVENED BY PATH TO CREATE A STABLE, HIGH-QUALITY SOURCE OF ARTEMISININ. SEMISYNTHETIC ARTEMISININ WILL COMPLEMENT THE BOTANICAL SUPPLY AND HAS HELPED TO STRENGTHEN THE SUPPLY CHAIN, STABILIZE PRICING, AND ENSURE AVAILABILITY. IN ADDITION, WE CONTINUED WORK TO TEST NEW, AND OPTIMIZE EXISTING, TREATMENTS THAT LESSEN THE BURDEN OF ENTERIC (INTESTINAL) DISEASES IN CHILDREN. THIS INCLUDES RESEARCH AND DEVELOPMENT OF SAFE AND EFFECTIVE NEW THERAPEUTICS FOR CRYPTOSPORIDIUM INFECTION, A LEADING CAUSE OF DEADLY DIARRHEAL DISEASE AMONG YOUNG CHILDREN THAT CAN CONTRIBUTE TO CHRONIC MALNUTRITION, STUNTED GROWTH, AND DELAYED MENTAL DEVELOPMENT. WITH GLOBAL PARTNERS, WE ADVANCED THE DEVELOPMENT OF A LONG-ACTING INJECTABLE FORMULATION OF PRE-EXPOSURE PROPHYLAXIS (PREP) TO PREVENT HIV INFECTION. SUCH FORMULATIONS HAVE THE POTENTIAL TO IMPROVE UPTAKE AND ADHERENCE OF HIV PREP AND COULD EXPAND THE GLOBAL TOOLBOX OF PREVENTION INTERVENTIONS, PROVIDING SAFE AND EFFECTIVE CHOICES TO ADDRESS DIFFERENT CIRCUMSTANCES AND PREFERENCES.PATH ALSO CONTINUED AN INTERNATIONAL EFFORT TO EXPAND THE USE OF A PROVEN ANTISEPTIC, CHLORHEXIDINE, INTO A NEW FORMULATION FOR USE ON BABIES' NEWLY CUT UMBILICAL CORDS. BETWEEN 2015 AND 2030, AN ESTIMATED 1,004,000 NEONATAL LIVES COULD BE SAVED EACH YEAR WITH GREATER USE OF CHLORHEXIDINE, AT A COST OF LESS THAN 50 CENTS A DOSE. PATH IS HELPING TO SUPPORT MORE THAN 20 COUNTRIES TO ADOPT THE DRUG AND INCREASE LOCAL PRODUCTION.FOR PATH'S BROAD DEVICES AND TOOLS PORTFOLIO, WE WORK WITH THE PEOPLE WE SERVE TO DEVELOP, ADAPT, AND INTRODUCE SOLUTIONS THAT IMPROVE MATERNAL, NEWBORN, AND REPRODUCTIVE HEALTH; NUTRITION; VACCINE DELIVERY; WATER AND SANITATION; AND MORE.THIS YEAR, WE CONTINUED TO DEVELOP AND INTRODUCE EFFECTIVE, USER-CONTROLLED CONTRACEPTIVE OPTIONS FOR THE 222 MILLION WOMEN WORLDWIDE WHO WANT TO AVOID PREGNANCY BUT ARE NOT USING MODERN CONTRACEPTION. THE CAYA CONTOURED DIAPHRAGM, DEVELOPED BY PATH AND OUR PARTNERS AS THE SILCS DIAPHRAGM, RECEIVED REGULATORY APPROVAL IN CANADA. IN ADDITION, MARKET CLEARANCE BY THE US FOOD AND DRUG ADMINISTRATION OPENED THE DOOR FOR SUBSEQUENT INTRODUCTION IN THE UNITED STATES IN 2015, PAVING THE WAY FOR INTRODUCTION IN MORE DEVELOPING-COUNTRY MARKETS. THE CAYA DIAPHRAGM'S DESIGN AND SPECIFICATIONS WERE INFORMED BY INPUT FROM WOMEN AND HEALTH CARE PROVIDERS. AS OF 2014, THE PRODUCT IS IN MORE THAN 15 COUNTRIES, INCLUDING EUROPEAN NATIONS. [CAYA IS A REGISTERED TRADEMARK OF KESSEL MEDINTIM GMBH.]PATH AND OUR PARTNERS ALSO ADVANCED WATER FILTERS AND TREATMENT DEVICES, INCLUDING THE GROUNDBREAKING MOUNTAIN SAFETY RESEARCH SE200 COMMUNITY CHLORINE MAKER, AVAILABLE IN 2015, WHICH CAN CREATE ENOUGH CHLORINE TO TREAT 55 GALLONS OF WATER AT THE TOUCH OF A BUTTON. [SE200 IS A REGISTERED TRADEMARK OF CASCADE DESIGNS, INC.]PATH ALSO WORKS TO DEVELOP AND INTRODUCE FAST, ACCURATE DIAGNOSTIC TECHNOLOGIES, INCLUDING TOOLS TO DETECT AND MONITOR CERVICAL CANCER, DIABETES, HIV, MALARIA, NEGLECTED TROPICAL DISEASES, TUBERCULOSIS (TB), AND OTHER DISEASES. 71547298 16148119 1083 PUBLIC HEALTH: PATH'S PUBLIC HEALTH PORTFOLIO FOCUSES ON SEVERAL KEY AREAS: REPRODUCTIVE HEALTH; MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION; NONCOMMUNICABLE DISEASES; MALARIA CONTROL AND ELIMINATION; AND HIV/AIDS AND TB PROGRAMS. IT ALSO SUPPORTS CROSS-PROGRAM COLLABORATIONS THAT INCREASE OUR IMPACT BY PUTTING OUR RESOURCES TO BEST USE. THROUGHOUT THESE EFFORTS, WE COLLABORATE WITH GOVERNMENTS, COMMUNITIES, AND CIVIL SOCIETY GROUPS AROUND THE WORLD TO STRENGTHEN THE LOCAL AND NATIONAL HEALTH SYSTEMS THAT PROVIDE CRUCIAL SERVICES. WE ALSO DEVELOP AND INTRODUCE PROVEN STRATEGIES TO IMPROVE HEALTH AND ENCOURAGE HEALTHY BEHAVIORS. IN 2014, WE CONTINUED OUR EFFORTS TO REDUCE THE BURDEN OF HIV/AIDS AND TB WORLDWIDE. WITH PARTNERS, WE WORKED TO DEVELOP APPROPRIATE, AFFORDABLE, AND EVIDENCE-BASED SCREENING TOOLS, DIAGNOSTICS, AND DRUGS; STRENGTHEN HEALTH SYSTEMS; AND INTEGRATE SERVICES FOR HIV AND RELATED CONDITIONS SUCH AS TB AND DIABETES. WE ALSO MOBILIZED LOCAL COMMUNITIES, PUBLIC AND PRIVATE PARTNERS, GOVERNMENTS, AND LEADERS TO INCREASE HEALTHY BEHAVIORS AND CONFRONT STIGMA AND GENDER-BASED VIOLENCE.FOR EXAMPLE, UNDER PROVIC, AN HIV/AIDS PROJECT IN THE DEMOCRATIC REPUBLIC OF THE CONGO, WE COUNSELED MORE THAN 166,390 PEOPLE ON HIV PREVENTION AND RISK REDUCTION AND MADE MORE THAN 131,730 PEOPLE AWARE OF THEIR HIV STATUS AND LINKED THEM TO SERVICES. WE SCREENED NEARLY 80,000 PREGNANT WOMEN FOR HIV AND HELPED 93 PERCENT OF THOSE WHO WERE POSITIVE BEGIN TREATMENT TO REDUCE THE RISK OF TRANSMISSION TO THEIR CHILDREN. AND WE REACHED THOUSANDS OF MEN AND WOMEN WITH SERVICES FOR TB, FAMILY PLANNING, AND NUTRITION AND PROVIDED COUNSELING AND SCREENING FOR GENDER BASED VIOLENCE. PATH'S COMPREHENSIVE STRATEGY TO ELIMINATE MALARIA IN AFRICA INCLUDES WORKING WITH NATIONAL MALARIA PROGRAMS IN A NUMBER OF COUNTRIES TO INCREASE THE USE OF PROVEN INTERVENTIONS, SUCH AS INSECTICIDE-TREATED BED NETS; STRENGTHEN QUICK AND EFFECTIVE CASE MANAGEMENT; GIVE MORE PEOPLE ACCESS TO DIAGNOSIS AND TREATMENT; FIND NEW WAYS TO REMOVE THE MALARIA PARASITE FROM POPULATIONS COMPLETELY; AND BUILD STRONG REPORTING SYSTEMS. IN 2014, WE PARTNERED WITH THE ZAMBIAN MINISTRY OF HEALTH TO RESEARCH NEW WAYS TO MONITOR AND ELIMINATE MALARIA IN AREAS WHERE PRIOR EFFORTS HAVE ALREADY LOWERED RATES. FOR INSTANCE, WE ARE EXPLORING THE EFFICACY OF TREATING ENTIRE COMMUNITIES WITH SAFE AND EFFECTIVE ANTIMALARIA DRUGS. IN SENEGAL, PATH AND OUR PARTNERS ARE SUPPORTING HEALTH CARE WORKERS TO CREATE "MALARIA-FREE ZONES" BY INVESTIGATING, IDENTIFYING, AND TREATING POCKETS OF SUSPECTED CASES BEFORE THEY GROW. IN AREAS WITH MORE INFECTIONS, WORKERS ALSO SCREEN ALL PEOPLE WITH FEVERS, TEST ENTIRE COMMUNITIES, AND PROVIDE TREATMENT. IN 2014, WE EXPANDED OUR EFFORTS TO FOUR NEW REGIONS, AND WE ARE MONITORING RESULTS.OUR REPRODUCTIVE HEALTH PROGRAM CONTINUED ITS WORK TO STRENGTHEN ACCESS TO FAMILY PLANNING, IMPROVE SCREENING AND TREATMENT FOR CERVICAL AND BREAST CANCERS, PREVENT SEXUALLY TRANSMITTED INFECTIONS, ADVOCATE FOR HEALTH SERVICES AND SUPPLIES, INTRODUCE CONTRACEPTIVE TECHNOLOGIES, AND ENCOURAGE HEALTHY BEHAVIORS. A KEY FOCUS IS ENSURING THAT WOMEN HAVE ACCESS TO A VARIETY OF SAFE AND AFFORDABLE CONTRACEPTIVE OPTIONS. IN AN IMPORTANT MILESTONE, PILOT INTRODUCTIONS OF A GROUNDBREAKING NEW FORM OF INJECTABLE CONTRACEPTION, SAYANA PRESS, REACHED THOUSANDS OF WOMEN FOR THE FIRST TIME IN 2014. SAYANA PRESS COMBINES A LOWER-DOSE FORMULATION OF THE WIDELY USED INJECTABLE CONTRACEPTIVE DEPO-PROVERA WITH THE PATH-DEVELOPED UNIJECT INJECTION SYSTEM. FOR THE PILOT PROJECTS, PATH AND OUR PARTNERS TRAINED 3,000 HEALTH WORKERS IN FOUR COUNTRIES TO DELIVER THE CONTRACEPTIVE. BY THE END OF 2014, SAYANA PRESS WAS BEING USED BY THOUSANDS OF WOMEN ACROSS BURKINA FASO, NIGER, AND UGANDA; SENEGAL WAS ON THE VERGE OF INTRODUCTION. IN ADDITION, KEY HEALTH PARTNERS ANNOUNCED A SIGNIFICANT PRICE REDUCTION FOR SAYANA PRESS THAT WILL GIVE MILLIONS MORE WOMEN ACCESS TO THE CONTRACEPTIVE AT REDUCED OR NO COST.[SAYANA AND DEPO-PROVERA ARE REGISTERED TRADEMARKS OF PFIZER INC. AND/OR ITS AFFILIATES. UNIJECT IS A TRADEMARK OF BD.]OUR WORK INCLUDED SEVERAL PROJECTS TO PREVENT, DETECT, AND TREAT HUMAN PAPILLOMAVIRUS (HPV), THE PRIMARY CAUSE OF CERVICAL CANCER WORLDWIDE. IN UGANDA, WE SUPPORTED THE MINISTRY OF HEALTH TO IMPLEMENT A TOOLKIT OF APPROACHES, INCLUDING VACCINATION FOR YOUNG WOMEN, EFFECTIVE AND AFFORDABLE SCREENING TOOLS, AND NATIONAL POLICIES TO PRIORITIZE HPV. WE ARE ALSO PARTNERING TO ASSESS NEW TECHNOLOGIES THAT CAN IMPROVE DETECTION AND TREATMENT. IN GUATEMALA, PATH SUPPORTED THE MINISTRY OF PUBLIC HEALTH AND SOCIAL ASSISTANCE TO RELEASE NEW NATIONAL GUIDELINES FOR THE SCREENING AND PREVENTION OF CERVICAL CANCER. THE GUIDELINES CAN SAVE WOMEN'S LIVES BY GIVING HEALTH CARE WORKERS LEADING-EDGE APPROACHES TO STOP CANCER BEFORE IT STARTS.WE ALSO CONTINUE TO SERVE AS THE SECRETARIAT FOR THE REPRODUCTIVE HEALTH SUPPLIES COALITION, A GLOBAL PARTNERSHIP OF 300 PUBLIC, PRIVATE, AND NONGOVERNMENTAL ORGANIZATIONS WORKING TO EXPAND ACCESS TO SUPPLIES, SERVICES, AND OPTIONS FOR PREVENTING UNINTENDED PREGNANCIES AND SEXUALLY TRANSMITTED INFECTIONS. 2014 BROUGHT TREMENDOUS GROWTH IN OUR NONCOMMUNICABLE DISEASES (NCD) PROGRAM. WE ARE APPLYING OUR IN-COUNTRY EXPERTISE AND OUR KNOWLEDGE OF PRODUCT AND MARKET DEVELOPMENT, DIAGNOSTICS, AND HEALTH SYSTEMS STRENGTHENING TO ADDRESS THE GROWING HEALTH AND ECONOMIC CHALLENGES ASSOCIATED WITH RISING NCD PREVALENCE. OUR GOAL IS TO REDUCE PREVENTABLE ILLNESS AND DEATH BY INCREASING ACCESS TO PREVENTION AND CARE FOR THESE DISEASES. THIS YEAR, BUILDING ON OUR SUCCESSFUL WORK TO REDUCE THE BURDEN OF BREAST AND CERVICAL CANCERS IN LOW-RESOURCE COUNTRIES, WE INCREASED OUR EFFORTS IN DIABETES AND EXPANDED OUR PORTFOLIO TO INCLUDE HYPERTENSION. WE CURRENTLY HAVE MORE THAN A DOZEN ACTIVE NCD PROJECTS IN VARIOUS STAGES, FROM RESEARCH AND DEVELOPMENT TO IMPLEMENTATION. MANY OF THESE EFFORTS ARE IMPLEMENTED IN PARTNERSHIP WITH MINISTRIES OF HEALTH TO ADDRESS CHALLENGES IN PROVIDING NCD PREVENTION AND CARE. FOR EXAMPLE, THE NO EMPTY SHELVES PROJECT IS GATHERING EVIDENCE AND MOBILIZING STAKEHOLDERS TO IMPROVE THE AVAILABILITY AND AFFORDABILITY OF ESSENTIAL NCD MEDICINES AND TECHNOLOGIES IN LOW-RESOURCE SETTINGS WORLDWIDE, WITH AN INITIAL FOCUS ON DIABETES. PATH'S MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION PROGRAM CONTINUED TO WORK WITH PARTNERS TO DESIGN AND IMPLEMENT EVIDENCE-BASED TECHNOLOGIES AND APPROACHES THAT REDUCE MATERNAL AND CHILD ILLNESS AND DEATH AND GIVE CHILDREN THE BEST POSSIBLE START IN LIFE. OUR INTEGRATED AND COST-EFFECTIVE SOLUTIONS ARE REACHING MOTHERS AND CHILDREN IN 19 COUNTRIES ACROSS AFRICA, ASIA, EASTERN EUROPE, THE MIDDLE EAST, AND LATIN AMERICA AND THE CARIBBEAN. IN 2014, WE CONTINUED TO PLAY A CATALYTIC ROLE IN ENSURING THAT FORTIFIED RICE PRODUCED THROUGH OUR ULTRA RICE FORTIFICATION TECHNOLOGY REACHES CHILDREN AND FAMILIES WORLDWIDE. WE CONTINUED TO BOLSTER LOCAL PRODUCTION, ESTABLISH QUALITY ASSURANCE SYSTEMS, AND SUPPORT MARKETING. THIS YEAR, OUR EFFORTS ACHIEVED A MILESTONE IN BRAZIL: A STUNNING 2 MILLION PEOPLE REACHED SINCE INTRODUCTION. AND IN MYANMAR, WE'RE WORKING TO BUILD RICE-FORTIFICATION CAPACITY AND INCREASE CONSUMER DEMAND. [ULTRA RICE IS A REGISTERED TRADEMARK OF BON DENTE INTERNATIONAL, INC.]PATH IS A LEADER IN STRENGTHENING HUMAN MILK BANKING (HMB) TO ENSURE THAT VULNERABLE INFANTS HAVE ACCESS TO LIFESAVING DONATED BREAST MILK WHEN THEIR MOTHERS' OWN MILK ISN'T AVAILABLE. IN 2014, WE ADVANCED AN INNOVATIVE MODEL IN WHICH BANKS ARE NOT JUST DONATION SITES, BUT HUBS OF CARE THAT PROVIDE BREASTFEEDING SUPPORT, PROMOTE CRUCIAL SKIN-TO-SKIN CONTACT, AND ENGAGE COMMUNITIES. WE REFINED A LOW-COST SYSTEM, FONEASTRA, THAT USES MOBILE PHONES TO HELP HEALTH WORKERS PASTEURIZE MILK. IN SOUTH AFRICA, WE HELPED THE NATIONAL HMB ASSOCIATION SAFELY AND SUSTAINABLY EXPAND BANKING. AND WE RECEIVED FUNDING TO HELP THE GOVERNMENT OF INDIA DEVELOP NATIONAL HMB GUIDANCE AND TO ESTABLISH A LEARNING EXCHANGE THAT LINKS INDIAN STAKEHOLDERS WITH EXPERTS IN BRAZIL'S GLOBALLY RECOGNIZED HMB SYSTEM. 36892844 12416472 INTERNATIONAL DEVELOPMENTPATH'S ON-THE-GROUND EXPERIENCE ALLOWS US TO APPLY TAILOR-MADE SOLUTIONS TO URGENT HEALTH NEEDS IN THE COMMUNITIES WE SERVE. WE COLLABORATE WITH COUNTRY PARTNERS TO IMPLEMENT SUSTAINABLE, COUNTRY-OWNED INNOVATIONS THAT STRENGTHEN HEALTH SYSTEMS, ENCOURAGE HEALTHIER BEHAVIORS, AND FOSTER MORE EQUAL ACCESS TO CARE AND SERVICES. IN 2014, OUR INTERNATIONAL DEVELOPMENT PORTFOLIO SUPPORTED OFFICES IN 19 COUNTRIES. THIS WORK RANGED FROM SMALL-SCALE PILOTS TO LARGE, MULTI-COUNTRY EFFORTS. THROUGHOUT, OUR SOLUTIONS WERE DESIGNED TO COMPLEMENT EXISTING COUNTRY AND COMMUNITY STRENGTHS, PRIORITIES, AND PROGRAMS. EXAMPLES INCLUDE:OUR MEKONG REGIONAL PROGRAM, BASED IN HANOI, VIETNAM, WORKS TO IMPROVE HEALTH SYSTEMS AND TACKLE PERSISTENT HEALTH THREATS IN VIETNAM, MYANMAR, CAMBODIA, AND LAOS. WE WORK WITH GOVERNMENTS TO IMPROVE VACCINE DELIVERY SYSTEMS; INTRODUCE NEW VACCINES; ADDRESS INFECTIOUS DISEASES INCLUDING HIV, TB, AND MALARIA; IMPROVE SCREENING AND TREATMENT FOR NCDS SUCH AS HYPERTENSION; AND IMPROVE REPRODUCTIVE AND MATERNAL AND CHILD HEALTH. AMONG OTHER HIGHLIGHTS IN 2014, WE SUPPORTED NATIONAL LEADERS TO INTRODUCE THE JAPANESE ENCEPHALITIS VACCINE IN KEY DISTRICTS OF CAMBODIA AND LAOS. THIS AFFORDABLE, EFFECTIVE VACCINE, ADVANCED THROUGH THE WORK OF PATH AND OUR PARTNERS, REACHED AN ESTIMATED 14 MILLION CHILDREN IN THESE TWO COUNTRIES AND THROUGH SIMILAR EFFORTS IN INDIA.OUR HEALTHY MARKETS PROJECT IS HELPING THE GOVERNMENT OF VIETNAM BUILD A COMMERCIAL MARKET FOR CONDOMS, HIV TESTING, AND OTHER HEALTH PRODUCTS AND SERVICES. BY MAKING PRODUCTS ACCESSIBLE TO EVERYDAY CONSUMERS WHO CAN AFFORD THEM, THE PROJECT FREES THE GOVERNMENT TO FOCUS FUNDING ON THOSE WHO CANNOT.IN MYANMAR, PATH IS ALSO ADDRESSING MICRONUTRIENT DEFICIENCIES THROUGH THE INTRODUCTION OF FORTIFIED RICE. WE ARE WORKING WITH PARTNERS TO SUPPORT FAVORABLE POLICY, DEVELOP LOCAL PRODUCTION, IMPROVE DISTRIBUTION, AND BUILD MARKETING AND PROMOTION CHANNELS.IN SENEGAL, WE ARE PARTNERING CLOSELY WITH THE NATIONAL MINISTRY OF HEALTH TO STRENGTHEN THE COUNTRY'S HEALTH SYSTEMS. THIS INCLUDES BUILDING THE CAPACITY OF INDIVIDUAL MINISTRY OF HEALTH DIVISIONS AND IMPROVING KEY HEALTH SYSTEMS AND PROCESSES. IN 2014, OUR RELATIONSHIPS AND EXPERIENCE PROVED CRUCIAL TO THE FIGHT AGAINST EBOLA. PATH PLAYED A MAJOR ROLE IN SUPPORTING THE MINISTRY OF HEALTH TO SET UP A NATIONAL EMERGENCY OPERATIONS CENTER AND DEVELOP TREATMENT GUIDELINES, SURVEILLANCE PROCESSES, AND OTHER SYSTEMS AND PROCEDURES TO RESPOND TO THE THREAT.PATH'S MALARIA CONTROL AND ELIMINATION PROGRAM (MACEPA) CONTINUES TO SUPPORT THE COUNTRY AS IT DRAWS CLOSER TO ELIMINATING MALARIA. IN SENEGAL, WE ARE BUILDING THE SURVEILLANCE SYSTEMS NECESSARY TO FIND AND TREAT NEW CASES QUICKLY-BREAKING THE CYCLE OF TRANSMISSION. THIS INCLUDES SUPPORTING FIELD WORKERS WHO GO HOUSE TO HOUSE, TESTING PEOPLE AND INVESTIGATING CASES. WITH PATH HELP, WORKERS USE AN ELECTRONIC SYSTEM TO UPLOAD THEIR FINDINGS TO A COMMON DATABASE. THE RESULT IS A REAL-TIME CASE MAP, ALLOWING LEADERS TO BETTER PLAN AND TARGET RESOURCES AND RESPOND MORE QUICKLY TO POTENTIAL OUTBREAKS.IN ADDITION, WE ARE HELPING TO BRING MODERN FAMILY PLANNING TO THE ESTIMATED 40 PERCENT OF SENEGALESE WOMEN WITHOUT ACCESS. THIS YEAR, SENEGAL WAS ONE OF FOUR COUNTRIES WHERE SAYANA PRESS, A NEW FORM OF A POPULAR INJECTABLE CONTRACEPTIVE DEVELOPED BY PATH AND PARTNERS, WAS LAUNCHED. THE PRODUCT WILL BRING MILLIONS OF WOMEN A SAFE, EFFECTIVE NEW CHOICE IN FAMILY PLANNING.IN ZAMBIA, PATH IS STRENGTHENING NATIONAL HEALTH SYSTEMS AND TARGETING KEY HEALTH THREATS. MACEPA CONTINUED TO PARTNER WITH THE GOVERNMENT TO STRENGTHEN THE MALARIA PROGRAM THROUGH FIELD-TESTING NEW STRATEGIES TO DECREASE MALARIA TRANSMISSION, EFFICIENT PLANNING, SURVEILLANCE, AND OTHER AREAS CRUCIAL TO ELIMINATION. THROUGH THE MALARIACARE EFFORT, WE TRAINED LABORATORY WORKERS AND CLINICIANS TO TEST FOR AND TREAT MALARIA AND PROVIDED ONGOING SUPERVISION. OUR EFFORTS TO IMPROVE THE HEALTH OF WOMEN AND CHILDREN INCLUDED AN ASSESSMENT OF OPPORTUNITIES TO STOP THE TRANSMISSION OF SYPHILIS FROM MOTHERS TO BABIES. IN COLLABORATION WITH OTHER ADVOCATES, OUR ADVOCACY TEAM PERSUADED THE GOVERNMENT OF ZAMBIA TO ADOPT TWO NEW NATIONAL POLICIES THAT WILL IMPROVE THE HEALTH OF NEWBORNS BY GUIDING HEALTH WORKERS AND ENCOURAGING INCREASED GOVERNMENT FUNDING. TO IMPROVE IMMUNIZATION, WE WORKED THROUGH GAVI, THE VACCINE ALLIANCE, TO EVALUATE KEY BARRIERS TO IMMUNIZATION IN ZAMBIA. AND THROUGH THE BID INITIATIVE, WE CONTINUED A BROAD PORTFOLIO OF WORK TO IMPROVE THE COLLECTION AND USE OF HIGH-QUALITY IMMUNIZATION DATA. WORKING WITH OTHER PARTNERS, WE ALSO DEMONSTRATED THAT THE HPV VACCINE, WHICH CAN HELP PREVENT CERVICAL CANCER, CAN BE SUCCESSFULLY ADMINISTERED TO ADOLESCENT GIRLS WHO ATTEND SCHOOL. FINALLY, THE PATH-LED THRIVE PROJECT IMPROVED NUTRITION FOR PEOPLE LIVING WITH HIV/AIDS, PREGNANT WOMEN, AND ORPHANS AND VULNERABLE CHILDREN IN FOUR PROVINCES. WE TRAINED HEALTH WORKERS IN NUTRITION ASSESSMENT, COUNSELING, AND SUPPORT, AND WE INCREASED ACCESS TO KEY PRODUCTS AND SERVICES. IN 2014, FOR EXAMPLE, WE WORKED WITH OUR PARTNERS TO EXPAND THE AVAILABILITY AND MARKET VIABILITY OF HIGH-ENERGY PROTEIN SUPPLEMENT, OR "HEPS"-A NUTRIENT-RICH PORRIDGE. WE INCREASED HEALTH WORKERS' COMFORT WITH HEPS, RAISED PRODUCTION STANDARDS, AND ARE EXPLORING SUSTAINABLE MARKETING AND DISTRIBUTION. 10076043 3539407 20545 OTHER PROGRAM SERVICES: PATH'S ADVOCACY AND PUBLIC POLICY PROGRAM WORKS IN THE UNITED STATES; WITH MULTILATERAL HEALTH LEADERS ENGAGED IN GLOBAL POLICY AND PLANNING; AND WITH COUNTRIES AND COMMUNITIES AROUND THE WORLD. WE HELP POLICYMAKERS UNDERSTAND ISSUES AND MOTIVATE THEM TO COMMIT FUNDING, CRAFT POLICIES, AND SPONSOR INITIATIVES TO STRENGTHEN GLOBAL HEALTH EFFORTS. IN 2014, WE LED ADVOCACY EFFORTS FOR THE INCLUSION OF RESEARCH AND DEVELOPMENT (R&D) IN THE POST-2015 DEVELOPMENT AGENDA, AS WELL AS ENSURING SUPPORT FOR GLOBAL HEALTH R&D IN THE UNITED STATES AND EUROPE. OUR PROJECT TO PROVIDE ADVOCACY SUPPORT IN KEY PARTNER COUNTRIES SUCCEEDED IN ADVANCING HEALTH POLICIES WITH THE POTENTIAL TO IMPROVE THE HEALTH OF WOMEN AND CHILDREN. FOR EXAMPLE, IN THE INDIAN STATE OF UTTAR PRADESH, PATH WORKED WITH THE GOVERNMENT TO HELP APPROVE POLICIES THAT WOULD PROVIDE EMERGENCY TRANSPORT FOR WOMEN IN LABOR. INFANT AND MATERNAL MORTALITY RATES ARE HIGH IN THE STATE, IN PART DUE TO LACK OF TRANSPORTATION TO HOSPITALS. PATH'S ADVOCACY EFFORTS LED TO THE DEVELOPMENT OF AN EMERGENCY MEDICAL TRANSPORTATION FRAMEWORK THAT WILL HELP SAVE LIVES.MARKET DYNAMICS: OVER THE PAST YEAR, PATH ALSO ESTABLISHED A FORMAL MARKET DYNAMICS DEPARTMENT. MARKET DYNAMICS WORK ENCOMPASSES EFFORTS TO CHARACTERIZE MARKETS, ASSESS SHORTCOMINGS, AND DESIGN MARKET-BASED INTERVENTIONS TO IMPROVE HEALTH OUTCOMES. THIS WORK COMPLEMENTS PATH'S OTHER EFFORTS, SUCH AS PRODUCT DEVELOPMENT; BUILDS UPON OUR EXISTING STRENGTH IN COMMERCIALIZATION; ALIGNS EXPERTISE ACROSS TEAMS; AND EXPANDS OUR CAPACITY TO ADDRESS MARKET-BASED ISSUES. THE DEPARTMENT IS CURRENTLY LEADING WORK ON MALARIA DRUG SUPPLY STRATEGIES AND SUPPORTING OTHER PATH PROJECTS, INCLUDING ASSESSING MARKETS FOR SEVERAL NOVEL DIAGNOSTICS (FOR EXAMPLE, MALARIA POINT-OF-CARE DIAGNOSTICS) AND ADVOCATING FOR MARKET-BASED SOLUTIONS TO IMPROVE ACCESS TO MATERNAL, NEWBORN, AND CHILD HEALTH PRODUCTS. SPECIAL INITIATIVES: PATH IS ENGAGED IN A VARIETY OF PROJECTS THAT GALVANIZE OUR EXPERTISE AND RESOURCES AND THAT OF OUR GLOBAL PARTNERS TO SAVE MORE LIVES, MORE QUICKLY. THESE SPECIAL INITIATIVES INCREASE OUR IMPACT BY ALIGNING DIVERSE EFFORTS, BRINGING US CLOSER TO A WORLD WHERE HEALTH IS IN REACH FOR EVERY PERSON, NO MATTER WHERE THEY LIVE.OUR MALARIA CENTER OF EXCELLENCE, FOR EXAMPLE, COORDINATES WORK ACROSS OUR INNOVATION PLATFORMS (VACCINES, DRUGS, DIAGNOSTICS, DEVICES, AND SYSTEMS AND SERVICE INNOVATIONS) TO COMBAT MALARIA EVEN MORE EFFECTIVELY AND AGGRESSIVELY. BY ALIGNING AND FOCUSING OUR STRENGTHS, THE INITIATIVE WILL ACCELERATE MOMENTUM TOWARD ACHIEVING THE AUDACIOUS GOAL OF A WORLD WITHOUT MALARIA.IN 2014, WE ALSO LAUNCHED THE PATH-LED INNOVATION COUNTDOWN 2030 (IC2030) INITIATIVE. IC2030 IS REIMAGINING WHAT IS POSSIBLE IN GLOBAL HEALTH. IT AIMS TO IDENTIFY, EVALUATE, AND SHOWCASE HIGH-IMPACT TECHNOLOGIES AND IDEAS THAT CAN TRANSFORM GLOBAL HEALTH BY 2030. BY ENGAGING ENTREPRENEURS, INVESTORS, INNOVATORS, AND EXPERTS ACROSS SECTORS AND AROUND THE WORLD, THE PROJECT AIMS TO HELP DRIVE DECISION-MAKING AND INVESTMENTS IN GAME-CHANGING INNOVATIONS AND ACCELERATE PROGRESS TOWARD ACHIEVING THE UNITED NATIONS SUSTAINABLE DEVELOPMENT GOALS AND RELATED HEALTH TARGETS.PATH'S GLOBAL HEALTH INNOVATION HUB ALSO CONTINUES TO IMPROVE ACCESS TO HEALTH SOLUTIONS. THE HUB SUPPORTS LOCAL INNOVATORS IN COUNTRIES AROUND THE WORLD. DRAWING ON OUR EXPERTISE IN BRINGING TOGETHER THE BEST MINDS FROM ACROSS PUBLIC AND PRIVATE SECTORS, WE HELP INNOVATORS OVERCOME HURDLES-WHETHER IN PRODUCT DESIGN, CLINICAL VALIDATION, COMMERCIALIZATION, OR MARKET DEVELOPMENT-AND GET THEIR SOLUTIONS TO MORE PEOPLE IN RESOURCE-LIMITED COMMUNITIES. IN 2014, WE LAUNCHED THE HUB IN SOUTH AFRICA, WHERE WE STRENGTHENED OUR PARTNERSHIPS WITH SCIENTISTS, ENTREPRENEURS, COMPANIES, AND INVESTORS FOCUSED ON GLOBAL HEALTH INNOVATIONS. WE ALSO ESTABLISHED THE FUNDING NECESSARY TO LAUNCH A HUB IN INDIA IN 2015.IN 2014, IN RECOGNITION OF PATH'S LEADING ROLE IN HEALTH INNOVATION, THE BILL & MELINDA GATES FOUNDATION PROVIDED A GENEROUS INNOVATION FUND (IF) GRANT. THE GRANT WAS CREATED TO INSPIRE AND SUPPORT PATH TEAMS' BEST IDEAS AND CREATIVITY. AFTER SOLICITING IDEAS FROM ACROSS PATH, CREATING A SHORT LIST, AND INVITING STAFF TO VOTE, A PATH INNOVATION FUND TASK FORCE AND OUR EXECUTIVE TEAM SELECTED NINE INNOVATIONS FOR FUNDING. THROUGHOUT 2014, THE GRANT ADVANCED RESEARCH AND WORK TOWARD POTENTIAL SOLUTIONS IN NUTRITION, DIAGNOSTICS, MALARIA, VACCINES, AND OTHER HEALTH AREAS. 10076043 3539407 20545 227364723 1 1 0 1 0 0 0 0 0 1 1 0 0 0 0 0 0 1 0 1 1 1 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 0 1 X 246 0 1 746 1 0 1 BE CB CH CG ET FR GH IN MZ OC NU PE SZ TZ TH UG KE UP VM ZA SG SF UK 0 0 0 1 1 0 0 0 0 X 15 15 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AZ CA CT FL IL MA MD NJ NY NC OH OR PA TX VA VT WA X X OLIVIA POLIUS CHIEF FINANCIAL OFFICER 2062853500 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 DEAN ALLEN BOARD CHAIR 2.00 0.00 X X 0 0 0 GEORGE GOTSADZE BOARD VICE CHAIR 2.00 0.00 X X 0 0 0 EIVOR HALKJAER BOARD SECRETARY 2.00 0.00 X X 0 0 0 DAVID KING BOARD TREASURER 2.00 0.00 X X 0 0 0 JO ADDY DIRECTOR 2.00 0.00 X 0 0 0 KOFI AMEGASHIE DIRECTOR 2.00 0.00 X 0 0 0 PHYLLIS CAMPBELL DIRECTOR 2.00 0.00 X 0 0 0 ALEX CHIKA EZAH DIRECTOR 2.00 0.00 X 0 0 0 RAJENDRA VATTIKUTI DIRECTOR 2.00 0.00 X 0 0 0 KEVIN REILLY DIRECTOR 2.00 0.00 X 0 0 0 VINCENT MCGEE DIRECTOR 2.00 0.00 X 0 0 0 FELIX OLALE DIRECTOR 2.00 0.00 X 0 0 0 TSITSI MASIYIWA DIRECTOR (BEGAN 12/17/14) 2.00 0.00 X 0 0 0 IREENA VITTAL DIRECTOR (BEGAN 12/17/14) 2.00 0.00 X 0 0 0 YEHONG ZHANG DIRECTOR (BEGAN 12/17/14) 2.00 0.00 X 0 0 0 STEVEN B DAVIS PRESIDENT AND CEO 38.00 2.00 X 569984 0 43512 MICHAEL B KOLLINS CHIEF OPERATING OFFICER 40.00 0.00 X 275774 0 40645 OLIVIA POLIUS CHIEF FINANCIAL OFFICER 38.00 2.00 X 255770 0 39644 DAVID C KASLOW VP, PRODUCT DEVELOPMENT 38.00 2.00 X 378301 0 41432 JOHN W BOSLEGO GLOBAL PROG. LDR II (UNTIL 12/2/14) 40.00 0.00 X 328552 0 40363 AMIE E BATSON CHIEF STRATEGY OFFICER 39.00 1.00 X 275229 0 32472 RIKKA E TRANGSRUD COUNTRY PROGRAM LEADER II 40.00 0.00 X 272382 0 31254 ASHLEY J BIRKETT GLOBAL PROGRAM LEADER I 40.00 0.00 X 271008 0 26224 KATHLEEN M NEUZIL GLOBAL PROGRAM LEADER I 40.00 0.00 X 255164 0 35920 DANIEL LASTER GENERAL COUNSEL 38.00 2.00 X 250848 0 39180 ANURAG PRABHAKAR MAIRAL GLOBAL PROGRAM LEADER I 40.00 0.00 X 236991 0 38525 KATHRYN A O'DRISCOLL CHIEF H.R. OFFICER 40.00 0.00 X 223925 0 37734 AYORINDE ALBERT AJAYI VP, INTL. DEV. (UNTIL 9/10/14) 40.00 0.00 X 222691 0 30722 JANE E HUTCHINGS GLOBAL PROGRAM LEADER I 40.00 0.00 X 217735 0 38569 CARLOS CLINTON CAMPBELL GLOBAL PROGRAM LEADER I 40.00 0.00 X 206490 0 22662 JOHN SKIBIAK ASSOCIATE DIRECTOR II 40.00 0.00 X 388090 0 35254 GRANT N COLFAX GLOBAL PROGRAM LEADER I 40.00 0.00 X 284055 0 29573 TRAD M HATTON CHIEF OF PARTY 40.00 0.00 X 272736 0 25971 RAMONDA ANNE BYRKIT COUNTRY PROGRAM LEADER I 40.00 0.00 X 254930 0 32356 DUNCAN OWENS EARLE ASSOCIATE DIRECTOR II 40.00 0.00 X 249848 0 32227 5690503 0 694239 237 0 1 0 AEROTEK INC 7301 PARKWAY DRIVE S HANOVER MD 21076 STAFFING SERVICES 811419 WIDENET CONSULTING GROUP LLC 11400 SE 6TH ST 130 BELLEVUE WA 98004 CONSULTING 721903 NYHUS COMMUNICATIONS LLC 1525 4TH AVE 400 SEATTLE WA 98104 CONSULTING 470845 SLALOM LLC 821 2ND AVE STE 1900 SEATTLE WA 98124 CONSULTING 360018 RESOURCES GLOBAL PROFESSIONALS 17101 ARMSTRONG AVE 100 IRVINE CA 90074 STAFFING SERVICES 320038 21 35220 22856948 79718238 184281129 722100 286891535 HONORARIUM 900099 15328 15328 CONSULTANCIES 541900 5967 5967 SALES 900099 1083 1083 22378 1370599 1370599 57687644 97000 57219488 370357 468156 -273357 194799 194799 141900 35220 105259 36641 36641 5100 3239 1861 1861 REIMBURSEMENTS 900099 519092 519092 OTHER 900099 141068 141068 GAIN-FOREIGN EXCH. 900099 102971 102971 763131 289280944 22378 0 2367031 30755257 30755257 250504 250504 40866596 40866596 4779705 2263520 2493243 22942 80749839 48180820 31404940 1164079 7616783 7616783 11283728 1009697 10274031 6401023 231905 6169118 311708 86294 225414 388147 23687 364460 113288 26136 87152 266421 266421 10043281 6516284 3455486 71511 314518 151918 153915 8685 4658968 3542303 1070422 46243 1020432 491233 481825 47374 48980 48980 10248321 625861 9622460 18020598 15719728 2215508 85362 6494926 5991886 341775 161265 75698 75698 2489286 179178 2310108 339568 22259 317309 SUBCONTRACTS 25037206 23859661 585746 591799 EQUIP RENT & MAINT 5833787 4819336 977047 37404 FACILITIES ALLOC 0 9953020 -10314538 361518 LEAVE & BENS ALLOC 0 26131638 -26759258 627620 8215280 5617022 2566983 31275 276623848 227364723 46002048 3257077 13397133 27155160 40026863 85106641 254302858 225750342 7771974 12072596 2850259 2917489 33563347 16642765 18577714 16920582 148068288 125648641 223973 44795 603218 0 485822280 495616246 52731771 50802396 4335893 3404022 57067664 54206418 X 21836456 19517592 403540565 418505291 3377595 3386945 428754616 441409828 485822280 495616246 12657096 -1884 0 X 0 1 X 1 1 1 X 152434405 240628741 171536869 260656932 286891535 1112148482 152434405 240628741 171536869 260656932 286891535 1112148482 362632553 749515929 4380066 2797154 2295453 1577831 1370599 12421103 38502 38502 1557958 502596 730742 2432891 763131 5987318 1130595405 172419 0.66290 0.70730 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1207 221479 222686 276401162 276623848 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 197270 193545 106680 222686 720181 250000 250000 250000 250000 1000000 1500000 3098 1207 4305 9016994 9350 768184 390340 9404188 7806786 2550 1503301 295643 9016994 6868767 5392 932627 7806786 6671532 2700 194535 6868767 5943911 1790 725831 6671532 0.37000 0.36000 0.27000 0 0 19881814 7463795 12418019 10092316 7428727 2663589 3589217 1750243 1838974 16920582 PART V, LINE 4: PATH UTILIZES THE INVESTED INTEREST EARNINGS FROM THE ENDOWMENT AS AN IMPORTANT FUNDING SOURCE TO FUND NEW OPPORTUNITIES TO EXPAND ITS REACH AND IMPACT AS AN ORGANIZATION IN THE FIELD OF GLOBAL HEALTH, IN ACCORDANCE WITH PATH'S ENDOWMENT SPENDING POLICY. 1 CENTRAL AMERICA AND THE CARIBBEAN 1 1 MANAGEMENT & GENERAL 2136 CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICES PUBLIC HEALTH 186353 CENTRAL AMERICA AND THE CARIBBEAN 0 0 GRANTMAKING 125619 EAST ASIA AND THE PACIFIC 5 53 MANAGEMENT & GENERAL 1468082 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 2217011 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 2838917 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES PUBLIC HEALTH 1088502 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES OTHER 15144 EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING 3457996 EUROPE 3 27 MANAGEMENT & GENERAL 2112395 EUROPE 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 21478042 EUROPE 0 0 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 2932936 EUROPE 0 0 PROGRAM SERVICES PUBLIC HEALTH 5697140 EUROPE 0 0 PROGRAM SERVICES OTHER 76062 EUROPE 0 0 FUNDRAISING 2327 EUROPE 0 0 GRANTMAKING 23005012 MIDDLE EAST AND NORTH AFRICA 0 0 MANAGEMENT & GENERAL -405 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES PUBLIC HEALTH 136050 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTMAKING 53201 NORTH AMERICA 0 0 MANAGEMENT & GENERAL 16521 NORTH AMERICA 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 466724 NORTH AMERICA 0 0 PROGRAM SERVICES PUBLIC HEALTH 225042 NORTH AMERICA 0 0 PROGRAM SERVICES OTHER 2225 NORTH AMERICA 0 0 GRANTMAKING 182219 RUSSIA & THE NEWLY INDEPENDENT STATES 1 10 MANAGEMENT & GENERAL 493412 RUSSIA & THE NEWLY INDEPENDENT STATES 0 0 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 748659 RUSSIA & THE NEWLY INDEPENDENT STATES 0 0 PROGRAM SERVICES PUBLIC HEALTH 2362 RUSSIA & THE NEWLY INDEPENDENT STATES 0 0 PROGRAM SERVICES OTHER 16252 RUSSIA & THE NEWLY INDEPENDENT STATES 0 0 GRANTMAKING 54094 SOUTH AMERICA 1 2 MANAGEMENT & GENERAL 96818 SOUTH AMERICA 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 265117 SOUTH AMERICA 0 0 PROGRAM SERVICES PUBLIC HEALTH 466029 SOUTH AMERICA 0 0 GRANTMAKING 475908 SOUTH ASIA 6 63 MANAGEMENT & GENERAL 1445057 SOUTH ASIA 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 3382369 SOUTH ASIA 0 0 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 2871215 SOUTH ASIA 0 0 PROGRAM SERVICES PUBLIC HEALTH 528391 SOUTH ASIA 0 0 PROGRAM SERVICES OTHER 14333 SOUTH ASIA 0 0 FUNDRAISING 19237 SOUTH ASIA 0 0 GRANTMAKING 3238100 SUB-SAHARAN AFRICA 18 482 MANAGEMENT & GENERAL 10203240 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 6843688 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 18943397 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES PUBLIC HEALTH 15015023 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES OTHER 539705 SUB-SAHARAN AFRICA 0 0 FUNDRAISING 11056 SUB-SAHARAN AFRICA 0 0 GRANTMAKING 10274447 6 54 29 584 35 638 7941764 135791396 143733160 SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 23661 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 25764 CHECK/WIRE EUROPE PUBLIC HEALTH 64952 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 18610 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 46567 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 335294 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 8468 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 16347 CHECK/WIRE SUB-SAHARAN AFRICA OTHER 7802 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 498546 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 296515 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 16509 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 12507 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 29282 CHECK/WIRE SOUTH AMERICA PUBLIC HEALTH 7702 CHECK/WIRE RUSSIA AND NEIGHBORING STATES INTERNATIONAL DEVELOPMENT 54094 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 16079 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 15744 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 21633 CHECK/WIRE MIDDLE EAST AND NORTH AFRICA PUBLIC HEALTH 53201 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 52849 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 16664 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 23273 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 12249 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 8825 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 132050 CHECK/WIRE CENTRAL AMERICA AND THE CARIBBEAN PUBLIC HEALTH 74760 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 7576 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 261494 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 10975 CHECK/WIRE EAST ASIA AND THE PACIFIC PRODUCT DEVELOPMENT 5092 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 8025 CHECK/WIRE EAST ASIA AND THE PACIFIC INTERNATIONAL DEVELOPMENT 93851 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 378366 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 15556 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 20478 CHECK/WIRE EAST ASIA AND THE PACIFIC INTERNATIONAL DEVELOPMENT 8906 CHECK/WIRE EAST ASIA AND THE PACIFIC INTERNATIONAL DEVELOPMENT 70553 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 43357 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 19614 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 5329 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 6599 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 6088 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 61455 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 172097 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 25057 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 10475 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 13440 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 25917 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 7072 CHECK/WIRE EAST ASIA AND THE PACIFIC PRODUCT DEVELOPMENT 181636 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 16783 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 11447 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 11236 CHECK/WIRE SOUTH AMERICA PRODUCT DEVELOPMENT 47631 CHECK/WIRE EUROPE PUBLIC HEALTH 109064 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 34742 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 81758 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 26576 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 19775 CHECK/WIRE EAST ASIA AND THE PACIFIC PRODUCT DEVELOPMENT 70867 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 9192 CHECK/WIRE EAST ASIA AND THE PACIFIC INTERNATIONAL DEVELOPMENT 64522 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 8445 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 6297 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 6033 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 9700 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 43339 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 174900 CHECK/WIRE EUROPE OTHER 10000 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 40059 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 36192 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 652171 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 445431 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 6353 CHECK/WIRE EAST ASIA AND THE PACIFIC PRODUCT DEVELOPMENT 7800 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 6600 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 21484 CHECK/WIRE SUB-SAHARAN AFRICA OTHER 25379 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 46810 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 24936 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 23883 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 25158 CHECK/WIRE EAST ASIA AND THE PACIFIC PUBLIC HEALTH 801124 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 143666 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 24061 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 17076 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 27096 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 31999 CHECK/WIRE EAST ASIA AND THE PACIFIC PRODUCT DEVELOPMENT 177701 CHECK/WIRE EAST ASIA AND THE PACIFIC PRODUCT DEVELOPMENT 38287 CHECK/WIRE EUROPE PUBLIC HEALTH 20360 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 100758 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 61767 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 34321 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 8301 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 11604 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 42203 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 35440 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 21653 CHECK/WIRE SOUTH AMERICA PUBLIC HEALTH 13858 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 16859 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 9696 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 733020 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 174746 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 4391410 CHECK/WIRE EAST ASIA AND THE PACIFIC INTERNATIONAL DEVELOPMENT 58516 CHECK/WIRE SUB-SAHARAN AFRICA OTHER 30000 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 5192 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 38863 CHECK/WIRE SUB-SAHARAN AFRICA OTHER 47475 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 10000 CHECK/WIRE SUB-SAHARAN AFRICA OTHER 6000 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 12497 CHECK/WIRE EUROPE PUBLIC HEALTH 123594 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 24650 CHECK/WIRE EAST ASIA AND THE PACIFIC INTERNATIONAL DEVELOPMENT 111707 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 19619 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 39439 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 580700 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 1552397 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 30260 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 20827 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 69316 CHECK/WIRE EUROPE PUBLIC HEALTH 60000 CHECK/WIRE EUROPE PUBLIC HEALTH 105782 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 323717 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 1019121 CHECK/WIRE EUROPE PUBLIC HEALTH 504882 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 100000 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 77253 CHECK/WIRE SOUTH AMERICA PRODUCT DEVELOPMENT 9100 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 385099 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 16428 CHECK/WIRE EUROPE PUBLIC HEALTH 50000 CHECK/WIRE NORTH AMERICA PUBLIC HEALTH 88458 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 61698 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 19391 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 12331 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 14189 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 6378 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 11830 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 8335 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 13240 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 17851 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 9824 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 7574 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 14761 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 18285 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 23344 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 14457 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 12895 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 37438 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 811274 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 233045 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 24468 CHECK/WIRE SUB-SAHARAN AFRICA OTHER 5000 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 130000 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 12125 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 12180 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 16882 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 19029 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 33967 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 363819 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 6513 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 8307 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 28260 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 12552 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 178559 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 6286 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 16403 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 185570 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 9575 CHECK/WIRE SOUTH ASIA PUBLIC HEALTH 50401 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 221047 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 30081 CHECK/WIRE EUROPE INTERNATIONAL DEVELOPMENT 240463 CHECK/WIRE EUROPE PUBLIC HEALTH 876521 CHECK/WIRE EUROPE PUBLIC HEALTH 38706 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 18774 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 8860 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 267908 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 20814 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 12156 CHECK/WIRE SOUTH AMERICA PRODUCT DEVELOPMENT 255898 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 7417 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 9043 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 15923 CHECK/WIRE SOUTH ASIA PUBLIC HEALTH 9177 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 22231 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 20741 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 27073 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 87377 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 22516 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 8328 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 17637 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 13188 CHECK/WIRE NORTH AMERICA PUBLIC HEALTH 41211 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 115186 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 15222 CHECK/WIRE EAST ASIA AND THE PACIFIC PRODUCT DEVELOPMENT 85000 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 22546 CHECK/WIRE SOUTH AMERICA PUBLIC HEALTH 48567 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 8593 CHECK/WIRE CENTRAL AMERICA AND THE CARIBBEAN PUBLIC HEALTH 50859 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 8245 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 230430 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 8055 CHECK/WIRE SOUTH AMERICA INTERNATIONAL DEVELOPMENT 5880 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 123967 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 22793 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 10331 CHECK/WIRE EUROPE PUBLIC HEALTH 8260 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 12514 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 16220 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 18366 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 5175 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 24582 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 10072 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 17400 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 17560 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 20132 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 12847 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 20881 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 7493 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 877721 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 6271 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 14400 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 23404 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 16386 CHECK/WIRE EAST ASIA AND THE PACIFIC INTERNATIONAL DEVELOPMENT 1040941 CHECK/WIRE SOUTH AMERICA PUBLIC HEALTH 50000 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 8794 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 11059 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 273164 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 31928 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 31061 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 10494 CHECK/WIRE NORTH AMERICA PUBLIC HEALTH 26100 CHECK/WIRE SOUTH ASIA PUBLIC HEALTH 54000 CHECK/WIRE SOUTH AMERICA PUBLIC HEALTH 5000 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 16427 CHECK/WIRE EAST ASIA AND THE PACIFIC PRODUCT DEVELOPMENT 100000 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 411130 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 10410 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 14727 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 14057 CHECK/WIRE EAST ASIA AND THE PACIFIC PRODUCT DEVELOPMENT 5540 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 5264 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 9963 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 7348 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 7839 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 5212 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 8661 CHECK/WIRE SUB-SAHARAN AFRICA OTHER 25690 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 42268 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 250000 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 11635 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 12001 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 7776 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 320000 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 3300736 CHECK/WIRE EUROPE PUBLIC HEALTH 2712 CHECK/WIRE EUROPE OTHER 2353409 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 91684 CHECK/WIRE EAST ASIA AND THE PACIFIC PRODUCT DEVELOPMENT 54136 CHECK/WIRE EAST ASIA AND THE PACIFIC PRODUCT DEVELOPMENT 29972 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 15350 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 15184 CHECK/WIRE EAST ASIA AND THE PACIFIC PRODUCT DEVELOPMENT 58071 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 11961 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 9887 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 30939 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 8937 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 25986 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 14896 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 8305 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 12106 CHECK/WIRE SOUTH AMERICA INTERNATIONAL DEVELOPMENT 5859 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 23435 CHECK/WIRE SUB-SAHARAN AFRICA OTHER 25000 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 290187 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 11231 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 181236 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 28048 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 37549 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 5376 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 22634 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 92952 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 12781 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 42431 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 12723 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 11656 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 7548 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 15422 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 8176 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 21923 CHECK/WIRE SUB-SAHARAN AFRICA OTHER 5000 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 147061 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 280092 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 257347 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 56743 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 201868 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 219959 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 841382 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 34641 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 1602157 CHECK/WIRE EUROPE PUBLIC HEALTH 52208 CHECK/WIRE NORTH AMERICA PRODUCT DEVELOPMENT 26450 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 29942 CHECK/WIRE EAST ASIA AND THE PACIFIC PRODUCT DEVELOPMENT 24000 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 9686 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 11631 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 290300 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 35147 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 6764 CHECK/WIRE EAST ASIA AND THE PACIFIC PRODUCT DEVELOPMENT 302872 CHECK/WIRE EAST ASIA AND THE PACIFIC PUBLIC HEALTH 75000 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 20993 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 19171 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 18993 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 13007 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 10231 CHECK/WIRE SOUTH AMERICA PUBLIC HEALTH 10524 CHECK/WIRE SUB-SAHARAN AFRICA OTHER 5944 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 59745 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 292417 CHECK/WIRE EUROPE INTERNATIONAL DEVELOPMENT 295000 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 917344 CHECK/WIRE EUROPE PUBLIC HEALTH 42039 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 22984 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 12987 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 10628 CHECK/WIRE SUB-SAHARAN AFRICA INTERNATIONAL DEVELOPMENT 58781 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 21949 CHECK/WIRE SUB-SAHARAN AFRICA PUBLIC HEALTH 167409 CHECK/WIRE EAST ASIA AND THE PACIFIC INTERNATIONAL DEVELOPMENT -179 CHECK/WIRE EAST ASIA AND THE PACIFIC INTERNATIONAL DEVELOPMENT -12850 CHECK/WIRE 274 50 1 0 0 0 0 0 PART I, LINE 2: SUBRECIPIENTS MUST SUBMIT PROGRESS REPORTS THAT ARE REVIEWED BY RESPONSIBLE PATH PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS OR FOLLOW UP ON ANY AREA OF CONCERN. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE SCIENTIFIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. PATH ALSO USES CROSS-PROGRAM INDICATORS TO TRACK OVERALL ORGANIZATIONAL PERFORMANCE AND LINK OUR WORK AND THE WORK OF SUBRECIPIENTS TO SPECIFIC IMPROVEMENTS IN HEALTH-RELATED OUTCOMES. MONITORING THIS SET OF INDICATORS HELPS PATH SET FUTURE BENCHMARKS AND ADOPT BEST PRACTICES THAT IMPROVE PROGRAMMATIC EFFECTIVENESS OVER TIME. GOLF BENEFIT 177120 35220 141900 38218 54379 2786 9876 177120 35220 141900 38218 54379 2786 9876 105259 36641 1 ACCELOVANCE INC 2275 RESEARCH BOULEVARD SUITE 700 ROCKVILLE MD 20850 200956757 N/A 744175 PRODUCT DEVELOPMENT ADVANCED BIOSCIENCE LABORATORIES INC 9800 MEDICAL CENTER DRIVE BUILDING D ROCKVILLE MD 20850 621242262 N/A 178400 PRODUCT DEVELOPMENT AKROS INC - RESEARCH ANALYTICS 3350 LAZERA RANCH ROAD CHEYENNE WY 82007 263668995 N/A 309411 INTERNATIONAL DEVELOPMENT APPLIED STRATEGIES CONSULTING LLC 951 MARINERS ISLAND BLVD SUITE 400 SAN MATEO CA 94404 331026972 N/A 25876 PUBLIC HEALTH BASIC HEALTH INTERNATIONAL INC THE MOUNT SINAI MEDICAL CENTER ONE GUSTAV L LEVY PLACE PO BOX 1170 NEW YORK NY 10029 203408717 501(C)(3) 263348 PUBLIC HEALTH BOSTON UNIVERSITY ONE SILBER WAY BOSTON MA 02215 042103547 501(C)(3) 178517 PUBLIC HEALTH BOSTON UNIVERSITY ONE SILBER WAY BOSTON MA 02215 042103547 501(C)(3) 26887 PRODUCT DEVELOPMENT BROADREACH HEALTHCARE LLC 1655 NORTH FORT MYER DR SUITE 700 ARLINGTON VA 22209 861052728 N/A 309328 INTERNATIONAL DEVELOPMENT CASCADE DESIGNS INC 4000 FIRST AVENUE SOUTH SEATTLE WA 98134 910969695 N/A 9624 PRODUCT DEVELOPMENT CDC FOUNDATION CDC FOUNDATION 55 PARK PLACE NE SUITE 400 ATLANTA GA 30303 582106707 501(C)(3) 449939 PRODUCT DEVELOPMENT CHILDFUND INTERNATIONAL 2821 EMERYWOOD PARKWAY RICHMOND VA 23294 540536100 501(C)(3) 96066 PUBLIC HEALTH CHRISTIAN CONNECTIONS FOR INTERNATIONAL HEALTH 1329 SHEPARD DRIVE SUITE 7 STERLING VA 20164 541932761 501(C)(3) 79905 PUBLIC HEALTH CONRAD EASTERN VIRGINIA MEDICAL SCHOOL 1611 N KENT ST SUITE 806 ARLINGTON VA 22209 237053028 501(C)(3) 250000 PRODUCT DEVELOPMENT ECHODITTO INC ONE DAVIS SQUARE STE 302 SOMERVILLE MA 02144 200134367 N/A 81260 PUBLIC HEALTH ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION 1140 CONNECTICUT AVENUE NW WASHINGTON DC 20036 954191698 501(C)(3) 3138967 INTERNATIONAL DEVELOPMENT EMORY UNIVERSITY 201 DOWMAN DRIVE ATLANTA GA 30322 580566256 501(C)(3) 364418 PUBLIC HEALTH EMORY UNIVERSITY 201 DOWMAN DRIVE ATLANTA GA 30322 580566256 501(C)(3) 49135 PRODUCT DEVELOPMENT EXPRESSION ANALYSIS INC 4326 S ALSTON AVE 101 DURHAM NC 27713 522340631 N/A 25000 PRODUCT DEVELOPMENT FAMILY CARE INTERNATIONAL INC 45 BROADWAY SUITE 320 NEW YORK NY 10006 237413005 501(C)(3) 134908 PUBLIC HEALTH FHI 360 FHI 360 HEADQUARTERS 359 BLACKWELL ST SUITE 200 DURHAM NC 27701 237413005 501(C)(3) 743953 PUBLIC HEALTH FINA BIOSOLUTIONS LLC 9430 KEY WEST AVE SUITE 200 ROCKVILLE MD 20850 205448275 N/A 53568 PRODUCT DEVELOPMENT FINANCING FOR DEVELOPMENT 1800 MASSACHUSETTS AVENUE SUITE 400 400 WASHINGTON DC 20036 680683026 501(C)(3) 313956 PUBLIC HEALTH FOOD & DRUG ADMINISTRATION 10903 NEW HAMPSHIRE AVENUE SILVER SPRING MD 20993 530196965 GOVERNMENT 407170 PRODUCT DEVELOPMENT FRAUNHOFER USA CENTER FOR MOLECULAR BIOTECHNOLOGY 9 INNOVATION WAY SUITE 200 NEWARK DE 19711 383203030 501(C)(3) 230937 PRODUCT DEVELOPMENT FRED HUTCHINSON CANCER RESEARCH CENTER PO BOX 19024 SEATTLE WA 98109 237156071 501(C)(3) 142779 PRODUCT DEVELOPMENT GEORGE W BUSH INSTITUTE 2943 SMU BLVD DALLAS TX 75205 204119317 501(C)(3) 25000 PUBLIC HEALTH GLOBAL HEALTH INSIGHTS LLC 3 PETER COOPER ROAD APT MC NEW YORK NY 10010 263809493 N/A 69534 PUBLIC HEALTH GMMB INC 1200 WESTLAKE AVENUE N SUITE 1005 SEATTLE WA 98109 521305983 N/A 95463 PUBLIC HEALTH GREENEWORKS GLOBAL LLC 3733 WARREN STREET NW WASHINGTON DC 20016 800672849 N/A 31000 PUBLIC HEALTH HARVARD UNIVERSITY SCHOOL OF PUBLIC HEALTH 1033 MASSACHUSETTS AVE STE 3 CAMBRIDGE MA 02138 042103580 501(C)(3) -10450 PUBLIC HEALTH IBIS REPRODUCTIVE HEALTH 17 DUNSTER STREET SUITE 201 CAMBRIDGE MA 02138 030382773 501(C)(3) 105612 PUBLIC HEALTH INITIATIVES INC 264 BEACON STREET BOSTON MA 02116 042961350 N/A 113017 INTERNATIONAL DEVELOPMENT INOVIO PHARMACEUTICALS 1787 SENTRY PARKWAY WEST BLDG 18- SUITE 400 BLUE BELL PA 19422 330969592 N/A 50000 PRODUCT DEVELOPMENT INTERNATIONAL AIDS VACCINE INITIATIVE 110 WILLIAM ST 27TH FLOOR NEW YORK NY 10038 133870223 501(C)(3) 192630 PRODUCT DEVELOPMENT INTERNATIONAL PLANNED PARENTHOOD FEDERATION WESTERN HEMISPHERE REGION 125 MAIDEN LANE 9TH FLOOR NEW YORK NY 10038 131845455 501(C)(3) 39522 PUBLIC HEALTH INTRAHEALTH INTERNATIONAL 6340 QUADRANGLE DRIVE SUITE 200 CHAPEL HILL NC 27514 550825466 501(C)(3) 147908 PUBLIC HEALTH JHPIEGO 1615 THAMES STREET BALTIMORE MD 21231 237424444 501(C)(3) 1702770 INTERNATIONAL DEVELOPMENT JHPIEGO 1615 THAMES STREET BALTIMORE MD 21231 237424444 501(C)(3) 99998 PUBLIC HEALTH JHU BLOOMBERG SCHOOL OF PUBLIC HEALTH 615 N WOLFE STREET BALTIMORE MD 21205 131687001 501(C)(3) 482772 PRODUCT DEVELOPMENT JOHN SNOW INC 44 FARNSWORTH STREET BOSTON MA 02210 042578580 N/A 204467 PRODUCT DEVELOPMENT JOHN SNOW INC 44 FARNSWORTH STREET BOSTON MA 02210 042578580 N/A 7600 PUBLIC HEALTH JOHNS HOPKINS UNIVERSITY OFFICE OF RESEARCH ADMINISTRATION 615 N WOLFE STREET W1100 BALTIMORE MD 21205 131687001 501(C)(3) 494201 PRODUCT DEVELOPMENT JSIR&T 1616 NORTH FORT MYER DRIVE 11TH FLOOR ARLINGTON VA 22209 042578580 N/A 77418 PUBLIC HEALTH KYBELE INC 3524 YADKINVILLE ROAD 124 WINSTON SALEM NC 27106 900759003 501(C)(3) 408273 PUBLIC HEALTH LOYOLA UNIVERSITY CHICAGO 6339 N SHERIDAN ROAD CHICAGO IL 60660 361408475 501(C)(3) 149693 PRODUCT DEVELOPMENT MEDICAL CARE DEVELOPMENT INC 8401 COLESVILLE ROAD SUITE 425 SILVER SPRING MD 20910 016022787 501(C)(3) 2672982 PUBLIC HEALTH NEW YORK UNIVERSITY 726 BROADWAY FLOOR 10 ROOM 1024 NEW YORK NY 10003 135562308 501(C)(3) 81695 PRODUCT DEVELOPMENT NIH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES 6610 ROCKLEDGE DRIVE MSC 6612 BETHESDA MD 20892 520858115 GOVERNMENT 1443022 PRODUCT DEVELOPMENT NORTIS INC C4C NEW VENTURE FACILITY 4000 MASON RD ROOM 304 FLUKE HALL PO BOX 35214 SEATTLE WA 98195 680649212 501(C)(3) 60924 PRODUCT DEVELOPMENT PAN AMERICAN HEALTH ORGANIZATION 1889 F STREET SUITE 312 WASHINGTON DC 20006 237072046 501(C)(3) -62251 PRODUCT DEVELOPMENT PATH DRUG SOLUTIONS 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 943384500 501(C)(3) 798172 GENERAL SUPPORT PATHFINDER INTERNATIONAL NINE GALEN STREET SUITE 217 WATERTOWN MA 02472 530235320 501(C)(3) 442732 PUBLIC HEALTH POPULATION ACTION INTERNATIONAL 1300 19TH STREET NW WASHINGTON DC 20036 520812075 501(C)(3) 12409 OTHER POPULATION COUNCIL ONE DAG HAMMARSKJOLD PLAZA 3RD FLOOR NEW YORK NY 10017 131687001 501(C)(3) 1151403 PUBLIC HEALTH POPULATION SERVICES INTERNATIONAL 1120 19TH STREET NW SUITE 600 WASHINGTON DC 20036 560942853 501(C)(3) 624285 PUBLIC HEALTH POPULATION SERVICES INTERNATIONAL 1120 19TH STREET NW SUITE 600 WASHINGTON DC 20036 560942853 501(C)(3) 107241 PRODUCT DEVELOPMENT PUBLIC HEALTH INSTITUTE 555 12TH STREET 10TH FLOOR OAKLAND CA 94607 941646278 501(C)(3) 423465 PRODUCT DEVELOPMENT SABIN VACCINE INSTITUTE 2000 PENNSYLVANIA AVENUE SUITE 7100 7100 WASHINGTON DC 20006 061389829 501(C)(3) 100000 PRODUCT DEVELOPMENT SANARIA INC 9800 MEDICAL CENTER DRIVE SUITE A209 ROCKVILLE MD 20850 562354362 N/A 979589 PRODUCT DEVELOPMENT SAVE THE CHILDREN 501 KINGS HIGHWAY FAIRFIELD CT 06825 060726487 501(C)(3) 156007 PUBLIC HEALTH SAVE THE CHILDREN 501 KINGS HIGHWAY FAIRFIELD CT 06825 060726487 501(C)(3) 18000 PRODUCT DEVELOPMENT SEATTLE BIOMEDICAL RESEARCH INSTITUTE 307 WESTLAKE AVE N SUITE 500 SEATTLE WA 98109 910961784 501(C)(3) 1464598 PRODUCT DEVELOPMENT SHIFT LABS INC 1752 NW MARKET ST 211 SEATTLE WA 98107 454541971 N/A 8000 PUBLIC HEALTH TULANE EDUCATIONAL FUND THE ADMINISTRATORS OF THE 1430 TULANE AVENUE TB-32 NEW ORLEANS LA 70112 720423889 501(C)(3) 21670 PRODUCT DEVELOPMENT TULANE UNIVERSITY SCHOOL OF PUBLIC HEALTH AND TROPICAL MEDICINE 1440 CANAL ST NEW ORLEANS LA 70112 720423889 501(C)(3) 170975 PUBLIC HEALTH TULANE UNIVERSITY OFFICE OF GRANTS AND CONTRACTS ACCOUNTING 800 EAST COMMERCE ROAD SUITE 203 HARAHAN LA 70123 720423889 501(C)(3) 10778 INTERNATIONAL DEVELOPMENT UNITED NATIONS FUND FOR POPULATION ACTIVITIES 220 EAST 42ND STREET NEW YORK NY 10017 GOVERNMENT 124517 PUBLIC HEALTH UNITED STATES NAVAL MEDICAL RESEARCH CENTER 503 ROBERT GRANT AVE SILVER SPRING MD 20910 470100048 GOVERNMENT 647619 PRODUCT DEVELOPMENT UNITED STATES PHARMACOPEIAL CONVENTION USP HEADQUARTERS 12601 TWIN BROOK PARKWAY ROCKVILLE MD 20852 131656692 501(C)(3) 45567 PRODUCT DEVELOPMENT UNIVERSITY OF ALABAMA AT BIRMINGHAM 701 20TH STREET SOUTH AB 1170 BIRMINGHAM AL 35294 636005396 501(C)(3) 200000 PRODUCT DEVELOPMENT UNIVERSITY OF FLORIDA 219 GRINTER HALL PO BOX 115500 GAINESVILLE FL 32611 596002052 501(C)(3) 18566 PRODUCT DEVELOPMENT UNIVERSITY OF MARYLAND BALTIMORE PO BOX 41428 BALTIMORE MD 21203 526002033 501(C)(3) 453519 PRODUCT DEVELOPMENT UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY GABLES ONE TOWER SUITE 650 CORAL GABLES FL 33146 590624458 501(C)(3) 223728 PRODUCT DEVELOPMENT UNIVERSITY OF NORTH CAROLINA 720 MARTIN LUTHER KING JR BLVD SUITE CHAPEL HILL NC 27599 566001393 501(C)(3) 305850 PRODUCT DEVELOPMENT UNIVERSITY OF SOUTH FLORIDA 4202 E FOWLER AVE TAMPA FL 33620 593102112 501(C)(3) 37888 PRODUCT DEVELOPMENT UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE 85 SOUTH PROSPECT STREET WATERMAN 217 BURLINGTON VT 05405 030179440 501(C)(3) 47000 PRODUCT DEVELOPMENT UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVE NE BOX 359472 SEATTLE WA 98195 916001537 501(C)(3) 349038 PRODUCT DEVELOPMENT UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVE NE BOX 359472 SEATTLE WA 98195 916001537 501(C)(3) 5000 OTHER UNIVERSITY OF WASHINGTON HARBORVIEW MEDICAL CENTER INFECTIOUS DISEASES RES HARBORVIEW MEDICAL CENTER 325 9TH AVE BOX 359932 SEATTLE WA 98104 916001537 501(C)(3) 11684 PRODUCT DEVELOPMENT VENTURE STRATEGIES INNOVATIONS 19200 VON KARMAN AVENUE SUITE 400 IRVINE CA 92612 262813021 501(C)(3) 60057 PRODUCT DEVELOPMENT VILLAGEREACH 2900 EASTLAKE AVE E STE 230 SEATTLE WA 98102 912082484 501(C)(3) 22295 PRODUCT DEVELOPMENT WALTER REED ARMY INSTITUTE OF RESEARCH 503 ROBERT GRANT DRIVE SILVER SPRING MD 20910 520664528 GOVERNMENT 2128235 PRODUCT DEVELOPMENT WIDENET CONSULTING GROUP 2910 1ST AVENUE S SUITE 200 SEATTLE WA 98134 264198815 N/A 333308 PUBLIC HEALTH WIDENET CONSULTING GROUP 2910 1ST AVENUE S SUITE 200 SEATTLE WA 98134 264198815 N/A 30173 OTHER WOMEN DELIVER 588 BROADWAY SUITE 5033 NEW YORK NY 10012 264462256 501(C)(3) 90000 OTHER WORKTANK ENTERPRISES LLC 400 EAST PINE STREET SUITE 301 SEATTLE WA 98122 912089916 N/A 88476 PUBLIC HEALTH WORLD VISION DC 300 I ST NE WASHINGTON DC DC 20002 951922279 501(C)(3) 1631107 INTERNATIONAL DEVELOPMENT WORLD VISION DC 300 I ST NE WASHINGTON DC DC 20002 951922279 501(C)(3) 25000 OTHER YALE UNIVERSITY GRANTS AND CONTRACT FINANCIAL ADMINISTRATION PO BOX 1873 NEW HAVEN CT 06508 060646973 501(C)(3) 92081 PRODUCT DEVELOPMENT 56 24 PUBLIC HEALTH 1 250504 PART I, LINE 2: SUBRECIPIENTS MUST SUBMIT PROGRESS REPORTS THAT ARE REVIEWED BY RESPONSIBLE PATH PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS OR FOLLOW UP ON ANY AREA OF CONCERN. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE SCIENTIFIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. PATH ALSO USES CROSS-PROGRAM INDICATORS TO TRACK OVERALL ORGANIZATIONAL PERFORMANCE AND LINK OUR WORK AND THE WORK OF SUBRECIPIENTS TO SPECIFIC IMPROVEMENTS IN HEALTH-RELATED OUTCOMES. MONITORING THIS SET OF INDICATORS HELPS PATH SET FUTURE BENCHMARKS AND ADOPT BEST PRACTICES THAT IMPROVE PROGRAMMATIC EFFECTIVENESS OVER TIME. X X 1 1 X X X X 0 0 0 0 0 0 0 1 0 STEVEN B DAVIS PRESIDENT AND CEO 421692 0 147592 0 700 0 31000 0 12512 0 613496 0 0 0 MICHAEL B KOLLINS CHIEF OPERATING OFFICER 275004 0 0 0 770 0 28133 0 12512 0 316419 0 0 0 OLIVIA POLIUS CHIEF FINANCIAL OFFICER 255000 0 0 0 770 0 30281 0 9363 0 295414 0 0 0 DAVID C KASLOW VP, PRODUCT DEVELOPMENT 377000 0 0 0 1301 0 28920 0 12512 0 419733 0 0 0 JOHN W BOSLEGO GLOBAL PROG. LDR II (UNTIL 12/2/14) 328552 0 0 0 0 0 31000 0 9363 0 368915 0 0 0 AMIE E BATSON CHIEF STRATEGY OFFICER 275004 0 0 0 225 0 31000 0 1472 0 307701 0 0 0 RIKKA E TRANGSRUD COUNTRY PROGRAM LEADER II 176241 0 0 0 96141 0 19696 0 11558 0 303636 0 0 0 ASHLEY J BIRKETT GLOBAL PROGRAM LEADER I 270783 0 0 0 225 0 13712 0 12512 0 297232 0 0 0 KATHLEEN M NEUZIL GLOBAL PROGRAM LEADER I 230089 0 25000 0 75 0 26576 0 9344 0 291084 0 0 0 DANIEL LASTER GENERAL COUNSEL 250008 0 0 0 840 0 26668 0 12512 0 290028 0 0 0 ANURAG PRABHAKAR MAIRAL GLOBAL PROGRAM LEADER I 236916 0 0 0 75 0 26061 0 12464 0 275516 0 0 0 KATHRYN A O'DRISCOLL CHIEF H.R. OFFICER 223295 0 0 0 630 0 25295 0 12439 0 261659 0 0 0 AYORINDE ALBERT AJAYI VP, INTL. DEV. (UNTIL 9/10/14) 220691 0 0 0 2000 0 25501 0 5221 0 253413 0 0 0 JANE E HUTCHINGS GLOBAL PROGRAM LEADER I 217735 0 0 0 0 0 26128 0 12441 0 256304 0 0 0 CARLOS CLINTON CAMPBELL GLOBAL PROGRAM LEADER I 187648 0 0 0 18842 0 21457 0 1205 0 229152 0 0 0 JOHN SKIBIAK ASSOCIATE DIRECTOR II 202619 0 0 0 185471 0 23641 0 11613 0 423344 0 0 0 GRANT N COLFAX GLOBAL PROGRAM LEADER I 218830 0 50000 0 15225 0 18017 0 11556 0 313628 0 0 0 TRAD M HATTON CHIEF OF PARTY 121085 0 0 0 151651 0 14530 0 11441 0 298707 0 0 0 RAMONDA ANNE BYRKIT COUNTRY PROGRAM LEADER I 173374 0 0 0 81556 0 20805 0 11551 0 287286 0 0 0 DUNCAN OWENS EARLE ASSOCIATE DIRECTOR II 217223 0 0 0 32625 0 26067 0 6160 0 282075 0 0 0 PART I, LINE 1A HOUSING ALLOWANCE & TAX INDEMNIFICATION ARE ONLY PROVIDED TO THOSE INDIVIDUALS WHO ARE EXPATRIATE EMPLOYEES. ALL BENEFIT PAYMENTS ARE MADE ACCORDING TO OUR EXPATRIATE POLICY. PART I, LINE 3: PATH ENGAGES WITH A CONSULTING FIRM TO REVIEW THE COMPENSATION FOR EACH OF THE SENIOR MANAGEMENT POSITION. PATH PROVIDES AN ANNUAL SALARY ADJUSTMENT EACH JANUARY BASED ON THE OVERALL LABOR MARKET MOVEMENT. PART I, LINE 7 BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II). X 25 182112 FMV X SUPPLIES 2 354007 COST OR SALES PRICE X SOFTWARE 1 153600 COST OR SALES PRICE X AUCTION ITEMS 31 29250 COST OR SALES PRICE X RAFFLE ITEMS 24 3131 COST OR SALES PRICE 0 0 1 0 PART I, COLUMN (B): THIS COLUMN REFLECTS THE NUMBER OF CONTRIBUTIONS. SCHEDULE M, PART I, LINES 27 AND 28: THESE LINES CONTAIN ITEMS DONATED FOR THE AUCTION AND RAFFLE EVENT. THIS EVENT IS FURTHER DISCUSSED IN SCHEDULE G, PART II. FORM 990, PART I, LINE 1 PATH IS THE LEADER IN GLOBAL HEALTH INNOVATION. AN INTERNATIONAL NONPROFIT ORGANIZATION, WE SAVE LIVES AND IMPROVE HEALTH, ESPECIALLY AMONG WOMEN AND CHILDREN. WE ACCELERATE INNOVATION ACROSS FIVE PLATFORMS-VACCINES, DRUGS, DIAGNOSTICS, DEVICES, AND SYSTEM AND SERVICE INNOVATIONS-THAT HARNESS OUR ENTREPRENEURIAL INSIGHT, SCIENTIFIC AND PUBLIC HEALTH EXPERTISE, AND PASSION FOR HEALTH EQUITY. BY MOBILIZING PARTNERS AROUND THE WORLD, WE TAKE INNOVATION TO SCALE, WORKING ALONGSIDE COUNTRIES PRIMARILY IN AFRICA AND ASIA TO TACKLE THEIR GREATEST HEALTH NEEDS. TOGETHER, WE DELIVER MEASURABLE RESULTS THAT DISRUPT THE CYCLE OF POOR HEALTH. OUR ROBUST MONITORING AND EVALUATION IS INTEGRAL TO THESE EFFORTS. AT EVERY STAGE, WE ASSESS AND ALIGN OUR PROGRESS AGAINST PROJECT, FUNDER, AND ORGANIZATIONAL TARGETS, AND EVALUATE OPPORTUNITIES TO INCREASE OUR EFFICINECY AND IMPACT. IN 2014, PATH AND OUR PARTNERS AND SUPPORTERS REACHED MORE THAN 160 MILLION PEOPLE WITH LIFESAVING HEALTH SOLUTIONS. OUR FUNDERS AND COLLABORATORS FROM ACROSS THE PUBLIC, PRIVATE, AND CORPORATE SECTORS ARE PIVOTAL TO OUR SUCCESS. THEIR CONTRIBUTIONS SUPPORT OUR WIDE-REACHING WORK TO ACCELERATE INNOVATION TO SAVE LIVES AND IMPROVE HEALTH WORLDWIDE. FORM 990, PART III, LINE 4A IN A KEY 2014 MILESTONE, WE LAUNCHED AN AFFORDABLE, EASY-TO-USE DIAGNOSTIC TEST THAT CAN QUICKLY DETECT PREVIOUS EXPOSURE TO THE PARASITE THAT CAUSES RIVER BLINDNESS (ONCHOCERCIASIS). THE TEST IS FAST, ACCURATE, AND TAILORED FOR USE IN THE POOR RURAL COMMUNITIES WHERE THE DISEASE IS MOST COMMON. PATH HAS WORKED WITH PARTNERS SINCE 2010 TO DEVELOP THE TEST AND BRING IT TO MARKET. WE TESTED AND REFINED THE DIAGNOSTIC, CONDUCTED LABORATORY AND FIELD EVALUATIONS, IDENTIFIED THE MANUFACTURER, AND HELPED ENSURE THE PRODUCT MET QUALITY AND PERFORMANCE REQUIREMENTS. THE TEST REPRESENTS THE FIRST IN A SUITE OF DIAGNOSTICS AIMED AT ELIMINATING NEGLECTED TROPICAL DISEASES, A GROUP OF ILLNESSES THAT AFFECT MORE THAN 1 BILLION PEOPLE WORLDWIDE. IN 2014, THE FIRST 15,000 TESTS WERE SHIPPED TO NIGERIA AND TOGO FOR USE IN DEMONSTRATION STUDIES, LAYING THE GROUNDWORK FOR FURTHER EXPANSION IN 2015. WE ARE ALSO EXPANDING OUR WORK TO BRING TO MARKET A NEW DUAL-DETECTION TEST FOR BOTH RIVER BLINDNESS AND LYMPHATIC FILARIASIS, A DISEASE THAT CAUSES DISFIGUREMENT AND DISABILITY AND OFTEN AFFECTS THE SAME COMMUNITIES AS RIVER BLINDNESS. AND WE ARE LEVERAGING OUR EXPERTISE AND GLOBAL NETWORK OF PARTNERS TO SPEED DEVELOPMENT OF ADDITIONAL DIAGNOSTIC TOOLS FOR NEGLECTED TROPICAL DISEASES. FINALLY, WE ARE PIONEERING THE USE OF DIAGNOSTICS FOR MALARIA ELIMINATION. WE ARE IMPROVING ACCESS TO AVAILABLE TESTS WHILE DEVELOPING NEW OPTIONS THAT PROVIDE ACCESS TO PROPER TREATMENT AND THAT CAN DETECT LOW LEVELS OF MALARIA INFECTION THAT MIGHT OTHERWISE BE MISSED. IN 2014, WE INCREASED THE USE OF HIGH-QUALITY MALARIA DIAGNOSIS AND TREATMENT IN 15 COUNTRIES IN AFRICA AND THE MEKONG REGION. OUR DIGITAL HEALTH SOLUTIONS GROUP CONTINUED TO WORK WITH GLOBAL HEALTH STAKEHOLDERS TO IDENTIFY, ADAPT, AND IMPLEMENT INFORMATION AND COMMUNICATIONS TECHNOLOGIES PRODUCTS, POLICIES, AND PROCESSES TO ENCOURAGE BETTER DATA USE AND DECISION-MAKING AND IMPROVE HEALTH. ACCOMPLISHMENTS IN 2014 INCLUDED SERVING AS A LEAD PARTNER IN THE BETTER IMMUNIZATION DATA INITIATIVE AND WORKING WITH TANZANIA'S MINISTRY OF HEALTH; GAVI, THE VACCINE ALLIANCE; AND OTHER PARTNERS TO INTRODUCE AN INEXPENSIVE, EASY-TO-USE, AND RELIABLE BARCODE TECHNOLOGY INTO THE NATIONAL LOGISTICS MANAGEMENT SYSTEM FOR VACCINES AND OTHER SUPPLIES. WE ALSO WORKED CLOSELY WITH VACCINE MANUFACTURERS TO UPDATE THE BARCODES USED ON VACCINE PACKAGING. OUR VISION IS THAT IN FIVE YEARS EVERY COUNTRY WILL BE ABLE TO TRACK PRODUCTS FROM MANUFACTURER TO RECIPIENT, IDENTIFY AND PREDICT STOCKOUTS, AND ENSURE THAT THE RIGHT GOODS ARE IN PLACE TO DELIVER LIFESAVING HEALTH IMPACT. FORM 990, PART III, LINE 4B THE FIVE-YEAR WINDOW OF OPPORTUNITY PROJECT (2011-2016) CONTINUED TO IMPROVE MATERNAL, NEWBORN, AND CHILD HEALTH (MNCH) AND DEVELOPMENT IN FIVE DISTRICTS IN SOUTH AFRICA AND MOZAMBIQUE. AMONG OTHER 2014 HIGHLIGHTS, WE CONTINUED WORK TO DEVELOP NATIONAL MNCH NUTRITION STRATEGIES AND SUPPORTED PROGRESS TOWARD A NEW NATIONAL EARLY CHILDHOOD DEVELOPMENT POLICY. AT THE DISTRICT LEVEL, WE STRENGTHENED COLLABORATIONS BETWEEN STAKEHOLDERS; IMPROVED DATA MANAGEMENT AND USE; ENGAGED COMMUNITIES TO IMPROVE HEALTH; AND PROVIDED SUPPORT AND TECHNICAL ASSISTANCE TO MORE THAN 40 COMMUNITY-BASED ORGANIZATIONS. SO FAR, THE PROJECT HAS TRAINED THOUSANDS OF HEALTH AND DEVELOPMENT PROFESSIONALS IN MNCH AND PROVIDED EDUCATION AND ASSISTANCE TO TENS OF THOUSANDS OF HOUSEHOLDS. TO DATE, OUR EFFORTS HAVE INCREASED WOMEN RECEIVING EARLY ANTENATAL CARE OVER STARTING NUMBERS IN PARTICIPATING AREAS, AND MORE CHILDREN ARE EXCLUSIVELY BREASTFED AT 14 WEEKS OF AGE, DECREASING THE BURDEN OF LIFE-THREATENING DIARRHEA. WE ALSO CONTINUED OUR BOLD PORTFOLIO OF EARLY CHILDHOOD DEVELOPMENT EFFORTS, WHICH HELP TO ENSURE THAT MORE CHILDREN RECEIVE THE STIMULATION (FROM CONVERSATION TO SIMPLE TOYS) THAT HELPS THEIR MINDS DEVELOP TO THEIR FULL POTENTIAL. IN 2014, WE BUILT ON MOMENTUM AND LESSONS LEARNED FROM PRIOR EFFORTS TO EXPAND OUR WORK IN KENYA AND MOZAMBIQUE. THE MAXIMISING THE QUALITY OF SCALING UP NUTRITION PROJECT SUPPORTED MORE THAN 20 PROJECTS TO ADDRESS UNDERNUTRITION IN 17 FOCUS COUNTRIES. THE PATH-LED CONSORTIUM IS IMPROVING HEALTH AND NUTRITION BY STRENGTHENING GOVERNMENT AND NATIONAL POLICIES; SCALING UP PROVEN INTERVENTIONS, SUCH AS FOOD SUPPLEMENTATION AND FORTIFICATION; AND INTEGRATING SYSTEMIC CHANGES, SUCH AS AGRICULTURAL AND WATER AND SANITATION IMPROVEMENTS, INTO EXISTING PROGRAMS. OUR PROJECTING HEALTH PROJECT ALSO MADE STRIDES. GETTING PEOPLE TO CHANGE THEIR HABITS IN FAVOR OF HEALTHIER BEHAVIORS IS ONE OF THE BIGGEST CHALLENGES IN GLOBAL HEALTH. PROJECTING HEALTH EMPOWERS LOCAL COMMUNITY MEMBERS TO PRODUCE, EDIT, AND STAR IN HEALTH EDUCATION VIDEOS CUSTOMIZED FOR LOCAL CONTEXTS AND DIALECTS. WITH A LOW-COST, PORTABLE PROJECTOR AND A WHITE SHEET FOR A SCREEN, THE VIDEOS ARE REACHING REMOTE COMMUNITIES IN ETHIOPIA AND INDIA WITH ACCURATE INFORMATION ON BREASTFEEDING, IMMUNIZATION, CHILDBIRTH, AND MORE. FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE 990 WAS SENT TO THE BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE PRESIDENT/CEO SIGNED THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C BOARD MEMBERS, PATH MANAGEMENT, AND ALL STAFF ABOVE A DESIGNATED LEVEL IN THE ORGANIZATION MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE ANNUALLY REVIEWS SALARY AND BENEFITS FOR EXECUTIVE EMPLOYEE POSITIONS AND PROVIDES GUIDANCE TO THE CEO ON COMPENSATION DECISIONS FOR EXECUTIVE POSITIONS. THE COMPENSATION AND BENEFITS FOR PATH'S PRESIDENT AND CEO ARE REVIEWED AND APPROVED BY THE ENTIRE BOARD OF DIRECTORS EACH YEAR AT THE DECEMBER BOARD MEETING. PATH ROUTINELY USES THE SERVICES OF EXTERNAL FIRMS TO ASSESS AND BENCHMARK EXECUTIVE COMPENSATION (PRESIDENT/CEO, VICE PRESIDENTS, AND EXECUTIVE TEAM MEMBERS). THE LAST MAJOR REVIEW WAS COMPLETED IN 2014, WHEN PATH ENGAGED MERCER (A COMPENSATION, BENEFITS, AND HUMAN RESOURCES CONSULTING FIRM) TO REVIEW CURRENT AND PROPOSED BASE SALARIES OF PATH'S PRESIDENT/CEO, VICE PRESIDENTS, AND EXECUTIVE TEAM MEMBERS. MERCER USED DATA FROM MULTIPLE SOURCES TO EVALUATE CURRENT AND PROPOSED BASE SALARIES FOR THESE POSITIONS. THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE REVIEWED THE MERCER REPORT AND APPROVED THE COMPENSATION PACKAGES FOR THE VICE PRESIDENTS AND EXECUTIVE TEAM. ADDITIONALLY, MERCER REVIEWED THE PROPOSED TOTAL COMPENSATION AND BENEFIT PACKAGE FOR THE PRESIDENT/CEO POSITION AND OBTAINED A SIGNIFICANT NUMBER OF DATA POINTS TO ASCERTAIN ITS REASONABLENESS AND APPROPRIATENESS. THE BOARD APPROVED THE COMMITTEE'S RECOMMENDATION FOR THE PRESIDENT/CEO'S TOTAL COMPENSATION PACKAGE. FORM 990, PART VI, SECTION C, LINE 19 PATH MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE. PATH VACCINE SOLUTIONS 2201 WESTLAKE AVENUE SEATTLE WA 98109 830431851 ADVANCE DEVELOPMENT OF VACCINES TO IMPROVE THE HEALTH OF CHILDREN WA 501(C)(3) LINE 11A PATH 1 PATH DRUG SOLUTIONS 280 UTAH AVENUE SUITE 250 SAN FRANCISCO CA 94080 943384500 DEVELOPMENT & DISTRIBUTION OF SAFE, EFFECTIVE, AND AFFORDABLE MEDICINES CA 501(C)(3) LINE 11A PATH 1 FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND 207 ROUTE DE FERNEY 1218 LE GRAND-S GENEVA SZ EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH SZ N/A N/A PATH 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 PATH VACCINE SOLUTIONS C 15586258 FMV PATH DRUG SOLUTIONS C 5119574 FMV PATH DRUG SOLUTIONS B 798172 FMV FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND C 2151116 FMV FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND B 5656857 FMV